Vertex Pharmaceuticals (VRTX) Inventory Average (2011 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Inventory Average of $1.7 billion for Q1 2026, up 34.63% year-over-year from $1.3 billion in Q1 2025, and up 4.22% quarter-over-quarter from $1.7 billion in Q4 2025.
Vertex Pharmaceuticals (VRTX) Inventory Average (2011 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Inventory Average history runs 16 years deep, the most recent figure standing at $1.7 billion for Q1 2026.
- In Q1 2026, Inventory Average rose 34.63% year-over-year to $1.7 billion; the TTM figure through Mar 2026 stood at $1.7 billion (up 34.63% YoY), while the FY2025 annual figure was $1.4 billion, up 48.76% from the prior year.
- Inventory Average for Q1 2026 stood at $1.7 billion, up from $1.7 billion in the prior quarter.
- The five-year high for Inventory Average was $1.7 billion in Q1 2026, with the low at $346.0 million in Q1 2022.
- The 5-year median for Inventory Average is $775.9 million (2024), against an average of $903.9 million.
- The sharpest annual moves came in 2022 and 2023: Inventory Average climbed 13.88% in 2022, then soared 70.95% in 2023.
- Vertex Pharmaceuticals' Inventory Average stood at $424.4 million in 2022, then surged by 68.18% to $713.8 million in 2023, then surged by 60.08% to $1.1 billion in 2024, then jumped by 45.0% to $1.7 billion in 2025, then rose by 4.22% to $1.7 billion in 2026.
- Business Quant data shows VRTX's Inventory Average at $1.7 billion in Q1 2026, $1.7 billion in Q4 2025, and $1.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.77 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.09 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 707.10 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 355,998.06 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 90.57 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 137.65 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.77 Bn |
| Mar 31, 2026 | 1.73 Bn |
| Dec 31, 2025 | 1.66 Bn |
| Sep 30, 2025 | 1.56 Bn |
| Jun 30, 2025 | 1.43 Bn |
| Mar 31, 2025 | 1.28 Bn |
| Dec 31, 2024 | 1.14 Bn |
| Sep 30, 2024 | 997.20 Mn |
| Jun 30, 2024 | 863.85 Mn |
| Mar 31, 2024 | 775.95 Mn |
| Dec 31, 2023 | 713.75 Mn |
| Sep 30, 2023 | 646.10 Mn |
| Jun 30, 2023 | 569.30 Mn |
| Mar 31, 2023 | 497.85 Mn |
| Dec 31, 2022 | 424.40 Mn |
| Sep 30, 2022 | 377.95 Mn |
| Jun 30, 2022 | 353.30 Mn |
| Mar 31, 2022 | 346.00 Mn |
| Dec 31, 2021 | 343.28 Mn |
| Sep 30, 2021 | 327.54 Mn |